{"id":4511,"date":"2020-11-11T11:00:00","date_gmt":"2020-11-11T10:00:00","guid":{"rendered":"https:\/\/encore-expertisecentrum.nl\/?p=4511"},"modified":"2020-11-29T21:00:16","modified_gmt":"2020-11-29T20:00:16","slug":"neptune-studie-voor-angelman-syndroom-afgerond","status":"publish","type":"post","link":"https:\/\/encore-expertisecentrum.nl\/en\/neptune-studie-voor-angelman-syndroom-afgerond\/","title":{"rendered":"NEPTUNE study for Angelman Syndrome completed"},"content":{"rendered":"<p>ENCORE participated in the international NEPTUNE study of the pharmaceutical company OVID (<a rel=\"noreferrer noopener\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04106557?term=NEPTUNE&amp;draw=2&amp;rank=6\" target=\"_blank\"><span style=\"text-decoration: underline;\">link<\/span><\/a>). In deze studie wordt onderzocht of het medicijn Gaboxadol een positief effect heeft op het dagelijks functioneren van kinderen met Angelman Syndroom. Dit is een gerandomiseerde placebo gecontroleerde studie, zodat duidelijk kan worden of het medicijn echt werkt. Een eerdere open studie, de STARS trial (<a rel=\"noreferrer noopener\" href=\"https:\/\/www.angelman.org\/data-and-analyses-phase-2-stars-clinical-trial-with-ov101\/\" target=\"_blank\"><span style=\"text-decoration: underline;\">link<\/span><\/a>) showed evidence of a beneficial effect, but this study did not provide definitive evidence due to its design. The desired number of participants has now been reached, so no more children are enrolled. We expect the first results in early 2021.<\/p>","protected":false},"excerpt":{"rendered":"<p>ENCORE participated in the international NEPTUNE study of the pharmaceutical company OVID. Four Dutch children participated in the study. The desired number of participants has now been reached, so no more children are enrolled. We expect the first results in early 2021.<\/p>","protected":false},"author":5,"featured_media":4515,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/posts\/4511"}],"collection":[{"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/comments?post=4511"}],"version-history":[{"count":7,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/posts\/4511\/revisions"}],"predecessor-version":[{"id":4756,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/posts\/4511\/revisions\/4756"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/media\/4515"}],"wp:attachment":[{"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/media?parent=4511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/categories?post=4511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/encore-expertisecentrum.nl\/en\/wp-json\/wp\/v2\/tags?post=4511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}